RemeGen’s telitacicept produced a markedly larger reduction in proteinuria versus placebo in a prespecified interim analysis of its Phase 3 IgA nephropathy trial. In NEJM-published results, patients receiving subcutaneous telitacicept 240 mg weekly showed a −58.9% change in 24-hour urinary protein-to-creatinine ratio at week 39 versus −8.8% with placebo. The relative difference between arms was −55.0% (95% CI −61.3 to −47.6; P<0.001). Kidney function, measured by estimated glomerular filtration rate, was broadly similar in direction, with −1.0% in telitacicept versus −7.7% in placebo. Adverse events were more frequent with telitacicept (89.3% vs 78.6%), though serious adverse events were lower (2.5% vs 8.2%). No unexpected safety findings were reported, and the trial is registered as NCT05799287.